Scope, Claim Coverage, and U.S. Patent Landscape for U.S. Patent 8,940,773 (Anemia Treatment Methods)
U.S. Patent 8,940,773 claims a method-of-treatment for anemia tied to a narrow set of specific chemical structures and variable-position substituent definitions. The independent claim 1 is a “Markush” style method claim covering administering a substituted pyridine-2-carboxamide/carbonyl-linked amino acetic acid–type scaffold (with salts), with R, R2, R6, and R7a/R7b constrained to small discrete sets. Dependent claims 2–3 further lock structure subsets and 4–10 name concrete compound embodiments (including multiple amide/ester variants with either no N-substitution, mono-methylamino, or dimethylamino). The practical patent protection is strongest for exact compound embodiments and close structural variants that keep R in the two listed aryl sets and preserve the restricted functional groups for R2/R6/R7a/R7b.
What does U.S. Patent 8,940,773 claim for anemia treatment in the U.S.?
Short answer: It claims administering a structurally constrained compound (or its pharmaceutically acceptable salt) to treat anemia.
Independent claim 1 scope in plain technical terms
Claim 1 is a method claim that covers:
- A patient “having anemia”
- “Administering” a compound with a defined structure
- A restricted set of substituent choices:
- R ∈ {
i) 3-chlorophenyl;
ii) 2,3-dihydrobenzo[1,4]dioxin-6-yl
}
- R2 ∈ {
i) O R6;
ii) N R7a R7b
}
- R6 ∈ { H, methyl, ethyl }
- R7a ∈ { H, methyl } and R7b ∈ { H, methyl }
- Includes pharmaceutically acceptable salts
Interpretation for claim coverage (what the claim is really doing):
- The claim breadth is driven by variable definitions, but the variables are tightly enumerated.
- “R2 is either OR6 or NR7aR7b” forces the chemistry at the corresponding position into either an ether/ester oxygen-linked group or an amide-type nitrogen-linked group, with R6 and R7a/R7b restricted to H/methyl/ethyl at those sites.
- The two R options for aryl substituent are a hard boundary. If a competitor uses a different aromatic/heteroaryl, non-infringement is likely.
Featured snippet takeaway
Claim 1 covers anemia treatment by administering only those compounds whose substituents match the enumerated R/R2/R6/R7a/R7b sets, including the named embodiments recited in claim 4.
How broad are claims 1–3: Markush boundaries and “allowed variants”
Claim 1 vs. claims 2–3
Claims 2 and 3 are dependent and further constrain the structure “wherein R2 is selected from …” and “wherein R6 …” and “wherein R7a/R7b …” but they keep the same enumerated values and the same two “R2 mode” options (OR6 vs NR7aR7b). Practically, claims 2–3:
- Reinforce that the covered subject matter must fall within the restricted functional group choices already defined in claim 1.
- Do not expand to additional substituents beyond the sets already stated for R, R2, R6, R7a, R7b.
Markush style boundaries
Even without the full drawn structure in the prompt, claim 1’s defined variables create four hard gates for infringement analysis:
- R gate: only two aryl substituent options are allowed.
- R2 gate: only two connectivity types allowed at that position (O-based group vs N-based group).
- R6 gate: only H/methyl/ethyl.
- R7a/R7b gate: each independently H or methyl (so the amine substitution pattern is limited to:
- NH (if both H, i.e., primary)
- N-methyl (if one methyl, one H, i.e., secondary)
- N,N-dimethyl (if both methyl, i.e., tertiary amide with dimethylamino substituent depending on the exact scaffold position)
Salt coverage
Each claim includes “or a pharmaceutically acceptable salt thereof,” meaning infringement exposure extends to:
- acid addition salts (common for basic heterocycles/amines)
- base salts (less common depending on functionality)
Which specific compounds are explicitly covered by claim 4 (and thus anchor enforcement)?
Claim 4 provides explicit compound selections. Those named embodiments are the most enforcement-relevant because they are not merely variable-interpretation; they are literal examples within the claim.
Claim 4 covered compounds (verbatim identifiers as provided):
- [5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester
- [5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
- 5-(3-Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide
- 5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide
- 5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide
plus pharmaceutically acceptable salts.
What these embodiments imply about R2/R7a/R7b
These embodiments map directly to the limited substitution pattern:
- The progression from amino (unsubstituted), to methylamino (mono-methyl), to dimethylamino (di-methyl) corresponds to the R7a/R7b enumerations (H/methyl).
- The methyl ester vs free acid aligns with the presence of an oxygen-linked substituent type vs a more polar acid form, and in many structures corresponds to the R2/R6 gating (again, exact mapping depends on the full drawn structure in the patent).
R aryl restriction emphasized
All five explicit embodiments in claim 4 use 3-chlorophenyl. The alternative R option in claim 1 (2,3-dihydrobenzo[1,4]dioxin-6-yl) is not listed in claim 4 as one of the named examples in your excerpt, but it remains within the independent claim scope via R definition.
Practical enforcement point:
Named embodiments reduce ambiguity in claim construction and provide clearer infringement anchors for compound-specific litigation.
Do claims 5–10 expand beyond claim 4?
Claims 5–10 are dependent on claim 4 and specify additional “compound has a structure” limitations. In the prompt, the structures for claims 5–10 are not legible textually (they appear as image placeholders), so the only reliable conclusion from the provided content is:
- Claims 5–10 remain within the compounds class anchored by claim 4.
- They narrow further, not broaden, because they are dependent and because the structure language is additional limitation.
Actionable takeaway for FTO:
A competitor that matches claim 4’s exemplified compounds is likely to face at least claim 1 and claim 4 exposure; if they also match the additional dependent-structure constraints in claims 5–10, they face higher risk.
What’s the likely patent “claim thesis” behind 8,940,773 (anemia treatment methods)?
The patent’s claims are method-of-use claims, not manufacturing process claims. They are designed to:
- Keep chemical structure boundaries tight via enumerated substituents.
- Tie infringement to the act of administering to an anemia patient, which can be implicated by clinical dosing and label-driven treatment regimens.
Implication for infringement strategy:
Even if a competitor can design around structure slightly, they may still face exposure if the competitor’s anemia regimen includes a covered compound embodiment or a close structural variant that still matches the enumerated substituent sets.
How do you map this claim set to a competitive product pipeline (generic or branded)?
White space and design-around levers
From the claim language, the main design-around levers are:
- Replace R with anything other than 3-chlorophenyl or 2,3-dihydrobenzo[1,4]dioxin-6-yl.
- Change R2 connectivity away from “OR6 vs NR7aR7b” functional forms as defined.
- Use an R6 substituent outside H/methyl/ethyl.
- Use N-substitution patterns beyond H/methyl at R7a/R7b (for example, ethyl at a nitrogen position, or larger substituents, would be outside the enumerated set).
High-risk “near matches”
High-risk structural variants are those that:
- keep R as one of the two allowed aryl groups
- keep R2 in the oxygen-or-nitrogen form
- keep N substitution limited to H and methyl at the defined N positions
These are the variants most likely to still satisfy claim 1’s variable ranges.
When does U.S. Patent 8,940,773 lose exclusivity (filing/term) and how does that impact generic entry?
No filing date, priority date, or specific patent expiration data is provided in the prompt. Without that, the exclusivity/expiration timeline cannot be computed from the information given.
So the patent litigation and Paragraph IV timing assessment cannot be completed accurately based only on the claim text provided.
What Orange Book status applies to U.S. Patent 8,940,773 and what does it mean for ANDA?
The prompt does not provide the Orange Book listing status, NDA holder, listed patents, or reference drug. Without those, ANDA/Paragraph IV launch risk cannot be mapped to a specific FDA product.
So a complete “Orange Book status of 8,940,773” section is not possible from the supplied content.
What is the U.S. litigation and settlement landscape for this patent?
The prompt does not include case captions, docket numbers, settlement agreements, or related litigation filings. Without those, litigation status cannot be stated.
How strong is the patent estate for this anemia scaffold (claim quality and enforceability signals)
Based on the claim language alone:
Strengths
- The claim is structurally anchored with enumerated substituent sets (fewer “stretch” arguments).
- It includes explicit embodiments (claim 4), which reduce factual disputes about mapping.
- It includes salts, covering common formulation salt choices.
Vulnerabilities
- Method-of-use enforcement can turn on proof of “administering to a patient having anemia,” which can be contested depending on labeling, clinical practice evidence, and whether the competitor’s regimen targets an anemia population.
- If competitors use compounds outside the enumerated R/R2/R6/R7a/R7b sets, design-around may be feasible without needing complex formulation work.
Claim-by-claim infringement checklist for U.S. Patent 8,940,773 (operator-ready)
| Claim |
What must be true for infringement |
Main “failure points” for a design-around |
| 1 |
Administer anemia-treatment compound that matches R, R2, R6, R7a/R7b enumerations; includes salts |
Use different R aryl; introduce R6 substituent outside H/methyl/ethyl; change R2 connectivity beyond OR6/NR7aR7b; change N-substitution beyond H/methyl |
| 2 |
Claim 1 + additional structural constraints tied to R2/R6/R7a/R7b selection |
Same as above; plus any dependent limitation beyond claim 1’s variable statements |
| 3 |
Claim 1 + dependent additional constraints |
Same as above |
| 4 |
Claim 1 + compound is one of five specifically named embodiments |
Modify any of the named scaffold/substitution patterns; alter amide vs ester/free acid form outside those enumerated examples |
| 5–10 |
Claim 4 + further narrowing structures |
Any mismatch to the additional dependent structure features |
Key Takeaways
- U.S. Patent 8,940,773 protects method-of-treatment for anemia by administering a highly constrained substituted scaffold with enumerated substituents.
- The enforceable scope is strongest where a competitor’s compound matches claim 4’s five explicit embodiments and salts.
- The primary claim-avoidance route is structural: move R off the two allowed aryl groups or move substitution patterns for R2/R6/R7a/R7b outside the enumerated options.
- A full timeline (expiration/exclusivity), Orange Book status, and litigation/Paragraph IV risk cannot be determined from the claim text alone.
FAQs
1) What structural features are most critical to avoid infringing claim 1 of U.S. 8,940,773?
Avoid using compounds where R is limited to only 3-chlorophenyl or 2,3-dihydrobenzo[1,4]dioxin-6-yl, and ensure the substituent pattern at R2/R6/R7a/R7b does not fit the enumerated OR6 vs NR7aR7b and H/methyl/ethyl constraints.
2) Does claim 4 provide a narrower “safe harbor” than claim 1?
No. Claim 4 narrows to five named embodiments, but claim 1 can still be infringed by other compounds that fall within the variable definitions even if they are not one of the claim 4 examples.
3) If a competitor uses a different aryl group than 3-chlorophenyl, can they design around?
Yes in principle, because claim 1 restricts R to exactly two aryl options; a different aryl would fall outside the enumerated R definition.
4) Are salts covered by the patent claims?
Yes. Each provided claim includes “or a pharmaceutically acceptable salt thereof,” extending coverage to covered salts of the claimed compounds.
5) Can a competitor avoid infringement by changing only formulation (salt/form) but keeping the same core structure?
Salt changes alone may not avoid infringement if the salt remains a pharmaceutically acceptable salt of a covered compound; the core structure and enumerated substituents are the key infringement determinants in claim 1.
References
- United States Patent 8,940,773, “Method for treating anemia,” claims as provided in prompt.
